CD19 and acute lymphoblastic leukemia: Similarly, in a study from Beijing, China, 52 adult patients with r/r ALL underwent reduced-intensity myeloablative allo-HCT after treatment with either CD19 or CD22 autologous CAR-T cells bearing a 4-1BB costimulatory domain (37).